Osmosis Investment Management UK Ltd Purchases Shares of 3,275 Natera, Inc. $NTRA

Osmosis Investment Management UK Ltd acquired a new stake in Natera, Inc. (NASDAQ:NTRA) in the second quarter, HoldingsChannel reports. The fund acquired 3,275 shares of the medical research company’s stock, valued at approximately $889,000.

Several other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after purchasing an additional 1,225,420 shares during the period. BlackRock Inc. acquired a new position in Natera during the second quarter worth approximately $2,962,770,000. Wellington Management Group LLP raised its stake in Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after buying an additional 2,420,263 shares during the period. State Street Corp raised its stake in Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after buying an additional 72,087 shares during the period. Finally, Coatue Management LLC lifted its position in shares of Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after buying an additional 2,463,008 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Down 1.3%

Shares of NTRA stock opened at $327.72 on Tuesday. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $333.56. The company has a market capitalization of $47.24 billion, a PE ratio of -240.97 and a beta of 1.51. The firm has a 50 day moving average price of $276.45 and a two-hundred day moving average price of $230.09.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.74) earnings per share. As a group, research analysts expect that Natera, Inc. will post -1.02 EPS for the current year.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 295 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $267.99, for a total transaction of $79,057.05. Following the transaction, the insider owned 183,774 shares in the company, valued at $49,249,594.26. This trade represents a 0.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the transaction, the insider owned 129,019 shares in the company, valued at $34,264,866.02. The trade was a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 177,955 shares of company stock valued at $40,704,193. 5.05% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. The Goldman Sachs Group initiated coverage on Natera in a research note on Friday, June 5th. They set a “neutral” rating and a $245.00 target price for the company. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Sanford C. Bernstein began coverage on Natera in a report on Friday, June 26th. They set an “outperform” rating and a $310.00 price target for the company. Stephens lifted their price objective on shares of Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Finally, Leerink Partners set a $330.00 price objective on shares of Natera in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average target price of $319.38.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.